*MZ Toutiao (美妆头条) · 2026-10-23 · Regulatory / Medical device* **原文：** 敷尔佳：重组Ⅲ型人源化胶原蛋白冻干纤维注册申请获受理 Voolga (敷尔佳) disclosed in a 16 September investor survey that its recombinant type III humanized collagen freeze-dried fibre has had its registration application formally accepted by the National Medical Products Administration, with the company aiming for approval in 2027, subject to the review timetable. Registration as a medical device would extend the medical-skincare group's regulated portfolio beyond its established topical dressing lines. Two supporting moves accompanied the update: the wholly owned subsidiary Shanghai Voolga Technology Development has obtained a Class III medical device distribution licence, and management said it is screening Class III device targets with synergies for potential acquisition — currently at an early stage of target identification. Detail --- Recombinant type III humanized collagen freeze-dried fibre Investor survey, Sep 16, 2026 Approval in 2027 Shanghai subsidiary wins Class III distribution licence Screening Class III device targets [Read the original article](https://www.mztoutiao.com/flashes/item/6000000000034/) ---

相关内容